• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Douglas Tsao Maintains Hold Rating on Outlook Therapeutics
23:41
Sep29
Outlook Therapeutics Completes Type A Meeting with FDA
13:37
Aug15
Outlook Therapeutics released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 1.505 M (forecast USD 1.663 M), actual EPS USD -0.5499 (forecast USD -0.3525)
03:00
Outlook Therapeutics released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 1.505 M and EPS of USD -1.3343
03:00
Jul1
Outlook Therapeutics Appoints Bob Jahr as CEO
12:06
Jun2
Outlook Therapeutics Launches First Bevacizumab Ophthalmic Formulation in Germany and the UK
11:44

Schedules & Filings

Schedules
Filings
Aug14
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.505 M, Net Income -20.15 M, EPS -0.5499

May15
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -46.36 M, EPS -1.5014

Feb14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income 17.38 M, EPS 0.717

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MIGI
15.045
+124.55%
+8.590
ATPC
0.1458
+114.41%
+0.078
PETS
3.335
+88.42%
+1.560
AXIL
9.076
+80.79%
+4.077
BEAT
2.520
+62.58%
+0.970
BTTC
5.302
+59.93%
+1.985
GEMG
9.360
+47.09%
+2.997
DHIL
170.475
+45.11%
+52.995
SMX
208.150
+42.28%
+61.850
VELO
12.047
+40.08%
+3.450
View More